不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
auto-HSCT 在结外 NK/T 细胞淋巴瘤中的作用
英文原题：The role of auto-HSCT in extranodal natural killer/T cell lymphoma.
查看英文原题
The role of auto-HSCT in extranodal natural killer/T cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
Auto-HSCT 确实是新诊断晚期 ENKL 的一种选择，但仍需进一步研究以实现更严格的疾病管理。
研究思路结论见上方概要
目的
自体造血干细胞移植（auto-HSCT）被认为是可选的巩固治疗，尤其适用于复发/难治性结外NK/T细胞淋巴瘤（ENKL），但目前其在新诊断晚期ENKL中的应用有限。
方法
我们收集了2014年1月至2023年12月期间在我院新诊断的51例晚期ENKL患者，其中26例接受auto-HSCT，25例接受化疗而非HSCT。我们总结了患者的特征，对51例患者进行了生存分析，并分析了auto-HSCT对ENKL患者的潜在获益。
结果
结果显示，中位随访时间39个月后，51例新诊断晚期ENKL患者的估计5年总生存期（OS）为73.4%，估计5年无进展生存期（PFS）为73.4%。接受auto-HSCT的患者5年OS（91.7%）和PFS（91.0%）与接受未行HSCT化疗的患者（OS 53.3%，PFS 54.5%）存在显著差异（p < 0.05）。单因素和多因素分析结果提示，仅化疗中l-asparaginase的使用对OS显示出显著影响，所关注的因素均未对PFS显示出显著影响。
展开英文摘要原文
OBJECTIVES
Autologous hematopoietic stem cell transplantation (auto-HSCT) is considered optional consolidation therapy especially for relapsed/refractory extranodal NK/T-cell lymphoma (ENKL), but its applications to newly diagnosed advanced-stage ENKL is currently limited.
METHODS
We collected 51 cases of newly diagnosed advanced-stage ENKL patients, including 26 with auto-HSCT and 25 with chemotherapy rather than HSCT, from our hospital between 2014/01 and 2023/12. We summarized the patients' characteristics, conducted survival analysis of the 51 cases, and analyzed the potential benefits of auto-HSCT to ENKL patients.
RESULTS
It shows that after a median follow-up time of 39 months, the estimated 5-year overall survival (OS) of the 51 newly diagnosed advanced-stage ENKL patients is 73.4%, and their estimated 5-year progression-free survival (PFS) is 73.4%. For patients receiving auto-HSCT, the 5-year OS (91.7%) and PFS (91.0%) are significantly different from those of patients receiving chemotherapy without HSCT (OS 53.3%, PFS 54.5%) ( p < 0.05). Univariate and multivariate analysis results suggest that only the l-asparaginase usage in chemotherapy showed significant impact on the OS, and none of concerned factors showed significant impact on the PFS.
CONCLUSIONS
Auto-HSCT is indeed an option to newly diagnosed advanced-stage ENKL, but further studies are still required for more strict disease management.
论文信息
- 作者
- Peng YY、Wang X、Liu L
- 单位
- Department of Hematology Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.China
- 期刊
- Open medicine (Warsaw, Poland)2024
- 原文标识
- PubMed 39381429 · DOI 10.1515/med-2024-1024
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →